A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females

Abstract

Background: Despite the fact that approximately 70% of Canadian women undergo cervical cancer screening at least once every 3 years, approximately 1,300 women were diagnosed with cervical cancer and approximately 380 died from it in 2008. This study estimates the effectiveness and cost-effectiveness of vaccinating 12-year old Canadian females with an AS04-adjuvanted cervical cancer vaccine. The indirect effect of vaccination, via herd immunity, is also estimated.

The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

“…These results were in line with the results from previous studies in other countries, which confirmed that the ICER of HPV vaccination has been considered to be sensitive to vaccine price [68,69] and discount rate [70][71][72]. Regarding duration of protection, since most of the long-term effectiveness of the vaccine has not been obtained yet, the authors were forced to use assumptions and/or intermediate outcomes for their model.…”

Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study

“…The HPV vaccine cost per dose including administration was $85. QALY-weights and unit costs were taken from the literature [25,26,[40][41][42][43][44][45][46][47][48] (see Supplementary Table 2). …”

Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan

“…A previously developed lifetime Markov cohort model with a 1-year cycle simulating the natural history of oncogenic HPV in cervical cancer (normal, HPV infection, cervical intraepithelial neoplasia [CIN], cervical cancer, cervical cancer deaths, other deaths) and the effect of screening and vaccination was adapted to reflect the Taiwanese settings [20,23,24]. An additional component to the initial model was appended by Demarteau and Standaert [25] to account for the low-risk HPV infections (including HPV types 6 and 11) that may result in CIN1 and/or GW.…”